Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification

• Status: Unknown status
• Trial end date: 2019-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Mydriatic eye drops are routinely used before phacoemulsification but they are not free of drawbacks. Several alternatives were tried to overcome their limitations.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dar El Oyoun Hospital
• Treatments: Atropine; Cyclopentolate; Epinephrine; Epinephryl borate; Ophthalmic Solutions; Oxymetazoline; Phenylephrine; Racepinephrine

Criteria

Inclusion Criteria:

• Cases of bilateral visually significant cataract

Exclusion Criteria:

• Poor pupil dilation(less than 6 mm diameter).

• History of previous eye surgery or trauma

• History of use of eye drops affecting pupil size such as pilocarpine.

• Known drug allergy to cyclopentolate,phenylephrine, atropine sulfate or epinephrine.

• Pediatric age group (less than 18 years old).

• Pupil abnormalities, such as anisocoria or neurological disorders.

• Associated glaucoma, uveitis, corneal, retinal or optic nerve disease.

• Cases scheduled for phacoemulsification under general anaesthesia (to exclude possible ocular and systemic effects or interactions of anaesthetic agents).

• Patients with bleeding tendency or on anti-coagulant therapy (because peribulbar and subconjunctival injections are used).